View an enhanced version of our Annual Report.
View an enhanced version of our Proxy Statement.
Request paper copies of the proxy materials by clicking the "online" or "email" buttons below, or by phone by dialing 866-648-8133.
Your vote is Important!
Please vote your proxy online now or by phone by
dialing 866-892-1702.
You must register to be eligible to participate in the meeting.
Date: March 13, 2025
Time: 5:00 PM ET
Register By: March 12, 2025 at 5:00 PM ET
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition.